Alzinova attends J.P. Morgan Healthcare Conference in San Francisco for meetings with industry partners and investors

"With the strong results we presented earlier this week and, in the spring of 2024, we have underscored the potential of ALZ-101 as a breakthrough treatment for Alzheimer's disease. We now look forward to presenting our latest developments to potential partners at this important event and accelerating discussions to maximize ALZ-101's development opportunities and bring this important treatment to those who need it most", says Tord Labuda, CEO Alzinova AB.

Alzinova's innovative vaccine candidate, ALZ-101, is aimed at neutralizing the toxic oligomeric forms of amyloid-beta – a key component in the development of Alzheimer's disease – the company looks forward to deepening contacts and exploring strategic collaboration. During the year, Alzinova has reported progress in the development of ALZ-101, where positive results from ongoing clinical studies strengthen the company's position in Alzheimer's research. At J.P. Morgan, Alzinova will conduct meetings with potential partners in the pharmaceutical industry, research institutions and investors to advance the development of its therapies against Alzheimer's disease.

About J.P. Morgan Healthcare Conference
The annual J.P. Morgan Healthcare Conference is organized on January 13–16, 2024. The conference is the largest international platform for companies like Alzinova to present their research and development to potential partners and investors. The conference is attended by both large global companies, innovative growing companies and investors with a focus on Life Science. Focusing on Alzinova's innovative vaccine candidate, ALZ-101, which is aimed at neutralizing the toxic oligomeric forms of amyloid-beta – a key component in the development of Alzheimer's disease – the company looks forward to deepening contacts and exploring strategic collaborations.

For more information, please contact:
Tord Labuda, CEO
E-mail: tord.labuda@alzinova.com

Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.

About Alzinova
Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer’s disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company’s Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com